Santosh Mahil Appointed CEO of Sekhmet Pharmaventures Backed by PAG, CX Partners, and Samara Capital

Santosh Mahil has been appointed as the Chief Executive Officer of Sekhmet Pharmaventures, an India-based API (Active Pharmaceutical Ingredient) investment platform. The company is backed by prominent investors PAG, CX Partners, and Samara Capital. Mahil will take on the leadership role to oversee operations and drive strategic initiatives for the organization.

Sekhmet Pharmaventures focuses on investments in the pharmaceutical sector, particularly in API manufacturing and development. With financial support from its key backers—PAG, CX Partners, and Samara Capital—the platform aims to strengthen its position in India’s growing pharmaceutical industry. Mahil’s appointment signals a new phase for the company as it seeks to expand its footprint and enhance its capabilities under his leadership.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 5, 2025

Related posts:

Numerical Differences Observed From Month 1 in Recent Study U.S. Solicitor General Advises Supreme Court Not to Review Oklahoma PBM Regulation Law Illumina Develops PromoterAI to Analyze Noncoding Genome for Rare Disease Insights Mice Demonstrate Sense of Embodiment with Artificial Limbs in Study Published by PLOS Biology

Author

Mark Chiang